Stocks · News reference

8-K filing — Xilio Therapeutics, Inc. (XLO)

Aug 12, 2026, 11:35 AMSEC EDGAR

Filed: 2026-08-12 AccNo: 0001193125-26-345753 Size: 368 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits

Read original source More stocks news

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

XLO

Source: edgar
Observed: Aug 12, 2026, 11:35 AM
Checked: Aug 12, 2026, 11:35 AM
Cadence: Captured once, then retained as an archive reference
Status: fresh

Keep reading

BenzingaAug 12, 2026, 11:37 AMBenzinga Newsdesk
Xilio Therapeutics Q2 EPS $(0.33) Beats $(0.59) Estimate, Sales $18.692M Beat $12.720M Estimate
Xilio Therapeutics (NASDAQ:XLO) reported quarterly losses of $(0.33) per share which beat the analyst consensus estimate of $(0.59) by 44.07 percent. This is a 85.27 percent increase over losses of $(2.24) per share
Read original at benzinga
XLO

8-K filing — Xilio Therapeutics, Inc. (XLO)

Connected markets

Related headlines

Xilio Therapeutics Q2 EPS $(0.33) Beats $(0.59) Estimate, Sales $18.692M Beat $12.720M Estimate